Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice

• Main Authors: Yasushi Honda (Author), Anna Ozaki (Author), Michihiro Iwaki (Author), Takashi Kobayashi (Author), Asako Nogami (Author), Takaomi Kessoku (Author), Yuji Ogawa (Author), Wataru Tomeno (Author), Kento Imajo (Author), Masato Yoneda (Author), Satoru Saito (Author), Yoji Nagashima (Author), Atsushi Nakajima (Author)
• Format: Book
• Published: Elsevier, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic disease. SGL5213, which is minimally absorbed and is restricted to the intestinal tract, is a potent intestinal sodium-glucose cotransporter 1 (SGLT1) inhibitor. In this study, we investigated the protective effect of SG...